docetaxel liposomal (LE-DT) / Insys Therap - LARVOL DELTA

Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer (MedPageToday) - "In an editorial accompanying the study...Stuart J. Wong, MD...noted that 'it is high time to shift the conversation from whether radiosensitizers are beneficial, to which regimen (if any) provides the most benefit and should define the standard of care.'...'On shooting down RT alone, docetaxel belongs in the armamentarium of go-to regimens, but since it was not compared head-to-head against prevailing alternatives, it should not be declared the lone standard,'...Wong suggested, adding that randomized trials are needed to see whether any non-cisplatin regimen prevails."

Media quote

Erlotinib as second line treatment for advanced non-small cell lung cancer(NSCLC):economic modeling (EM) results (ISPOR 2011) - Erlotinib could be considered as a dominant treatment strategy in 2nd line mNSCLC compared to docetaxel or pemetrexed under the Brazilian Private Healthcare System perspective

Cost analysis • Non Small Cell Lung Cancer • Oncology